Pneumococcal vaccine. [U.S. semyvalentnom pneumococcal

(PCV 7) (for example) was recommended for all children aged 223 months and the risk of children aged 2459 months in 2000. The normal dose of 4 in series 2, 4, June 1214 months of age. In February 2010, Pneumococcal vaccine congugate which protects against 6 additional serotypes were introduced (PCV 13 / brand: Prevnar 13) and may be provided instead of the original Prevnar. Similar ninth 10-valent vaccine were tested. Protection against pneumococcal infection is a good deep (especially septicemia and meningitis). However, if the child is exposed to serotype pneumococcus, which is not contained in the vaccine, he / she is not given any protection. This limitation, and the ability to capsular polysaccharide vaccine is associated with will promote uncovered serotypes led to research vaccines, which will provide all kind of protection. (Pneumovax is one brand) gives at least 85% protection to persons under 55 years, for five years or longer. Immunization is available to those at greatest risk of infection, including 65 years and older tend to be single vaccine dose of life, as there is a high risk of side effects if repeated. Standard 23-valent vaccine is not effective for children under two years. Currently, guidelines call for the administration of immunization at the age of 2 to 65 years if there are indications and the age of 65. If someone has received immunization at the age of 60 years, the guidelines call for one-time revaccination. Revaccination intervals show also for those with other conditions, such as or. [It was announced in February 2006 that the UK government introduce vaccination conjugated vaccine in children aged 2, 4 and 13 months. Expected to start Sept. 4, 2006 and will include changes to the immunization programs in general. In 2009, the European Agency for Medicinal Products has recommended 10-valent conjugated vaccine pneumcoccal for use in Europe .. 13-valent pneumococcal vaccine was introduced in accordance with the current immunization schedule United Kingdom in April 2010. [Pneumovax 23 is used and according to the percept of information about the patient, has reported 76% to 92% protective efficacy (Pneumococcal types 1, 2, 3, 4, 5, 6b **, 7F, 8, 9N, 9V ** , 10A, 11A, 12F, 14 **, 15B, 17F, 18C, 19A **** 19F, 20, 22F, 23F and 33F **** included where ** indicates the drug-resistant pneumococcal infections, these are 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae). [It is a program to accelerate the assessment and access to new pneumococcal vaccine in strattera online developing countries. PneumoADIP funded. Thirty HAVI countries expressed interest in participating in 2010. PneumoADIP aims to save 5. 4 million children in 2030. [Due to the geographical distribution of pneumococcal serotypes, it is necessary to conduct additional research to find the most effective vaccines for developing world populations. In a previous study, the most common pneumococcal serotypes or groups from developed countries were in descending order, 14, 6, 19, 18, 9, 23, 7, 4, 1 and 15. In the countries of this order was 6, 14, 8, 5, 1, 19, 9, 23, 18, 15 and 7. To further pneumococcal vaccine research and reducing child mortality, five of the Bill and Melinda Gates Foundation established the market earlier pilot commitment pneumococal vaccines worth U.S. $ 1. 5000000000 dollars. Commitments to the market a new approach to public funding of health care, aimed at stimulating the development and manufacture of vaccines for developing countries. There is currently research into producing vaccines than can be given in the nose rather than by injection. It is believed that this increases the effectiveness of vaccines and eliminates the need for injections. Development of serotype specific anticapsular monoclonal antibodies have also been investigated in recent years. These antibodies were shown to extend survival in murine models of pneumococcal infection is characterized by reduction in bacterial load and suppression of host inflammatory response. Additional research is Pneumococcal vaccine to find a vaccine that offers broad protection against pneumococcal infection. [[[.



